Medicine
Sancuso 3.1 mg/24 hours transdermal patch
Sancuso 3.1 mg/24 hours transdermal patch is a prescription medicine containing Granisetron for transdermal use, marketed by Cumberland Pharmaceuticals, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at 20°-25°C (68°-77°F), excursions permitted between 15°-30°C…
Key facts
- Active ingredient (INN)
- Granisetron
- Brand
- Sancuso
- Strength
- 3.1 mg/24 hours
- Dosage form
- Transdermal patch
- Route
- Transdermal
- Packs
- 168 h
- Marketing authorisation holder
- Cumberland Pharmaceuticals
- Manufacturer
- Cumberland Pharmaceuticals
- Origin register
- US FDA, United States
- Storage
- Store at 20°-25°C (68°-77°F), excursions permitted between 15°-30°C (59°-86°F). SANCUSO should be stored in the original packaging.
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- A04AA02 Granisetron
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 16 July 2024
- Identifiers
- RxCUI 825003, 825005DailyMed set ID 7379369a-03df-4ec3-8f2e-66645cc736d8NDC 66220-637Application NDA022198
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 168 h in 1 pouch | 66220-637-31 | Cumberland Pharmaceuticals | 16 July 2024 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Granisetron
Clinical summary
Granisetron is a serotonin-3 receptor antagonist indicated for the prevention of nausea and vomiting in adults receiving moderately and/or highly emetogenic chemotherapy regimens of up to 5 consecutive days duration. MedsAcross supplies Granisetron for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about GranisetronFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- SANCUSO prescribing information (Cumberland Pharmaceuticals) · U.S. National Library of Medicine, DailyMed
- Sancuso: European public assessment report (EPAR) · European Medicines Agency
Need Sancuso 3.1 mg/24 hours transdermal patch for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.